Compare Medpace Holdings Inc (MEDP) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Spotify Technology — how do they compare? Medpace Holdings Inc trades at $615.1 (market cap $16.82B), while Spotify Technology trades at $528 (market cap $108.22B). The key difference: Spotify Technology is far larger — about 6.4× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Spotify Technology for 111 Days on average.
| MEDP | SPOT | |
|---|---|---|
Market Cap | $16.82B | $108.22B |
Volume | 223,093 | 1,655,796 |
Sector | Health | Media |
52-Week High | $630.19 | $692.04 |
52-Week Low | $393.42 | $412.75 |
Typical Hold Time | 14 Days | 111 Days |
Enterprise Value | $16.44B | $98.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Spotify (SPOT) trades at $512.92, up 5.08% with strong bullish technical signals from moving averages. The company demonstrates robust fundamental momentum with revenue growing from $11.7B in 2022 to $17.2B in 2025, while achieving profitability with net income reaching $2.2B. Recent earnings show mixed results with Q2 2026 missing expectations, but analyst consensus remains overwhelmingly positive with 62% buy ratings and a $608.18 price target representing 19% upside potential.
The outlook remains favorable with projected 2026 revenue of $18.1B and net income of $3.3B, though risks include competitive pressures in streaming and recent stock volatility. Key catalysts include Q3 2026 earnings release on October 22, 2026, and continued gross margin expansion from 32.8% currently. Institutional sentiment appears constructive given the strong buy-side analyst coverage and improving cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
